Elbe Kliniken News Today : Breaking News, Live Updates & Top Stories | Vimarsana

The European Commission has approved single-agent nivolumab for use in the adjuvant treatment of adult and adolescent patients aged 12 years or older who have stage IIB or IIC melanoma and who have undergone complete resection.

Bristol myers squibb opdivoGina fusaroEuropean unionEuropean commissionBristol myers squibbMyers squibbSingle agent nivolumabStage iib or iic melanomaCheckmate 76k trialPeter mohrElbe kliniken